COVID-19: benefits and risks of passive immunotherapeutics

• Main Authors: Ankur Gupta (Author), Rashmi Karki (Author), Himanshu R Dandu (Author), Kuldeep Dhama (Author), Madan LB Bhatt (Author), Shailendra K Saxena (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respira...